MétaCan
Menu
Back to cohort
Record W7037370114

Editorial, News, Bio shares

2010· article· en· W7037370114 on OpenAlexaboutno aff

Bibliographic record

VenueTSpace (University of Toronto) · 2010
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicTransgenic Plants and Applications
Canadian institutionsnot available
Fundersnot available
KeywordsStock (firearms)Investment (military)AgricultureCredibilityTourism
DOInot available

Abstract

fetched live from OpenAlex

Australasian Biotechnology, Volume 7 Number 2, March/April 1997, pp.66-86 & 108-123 Editorial, News, Bio shares Code Number: AU97011 Size of Files: Text: 117.1K Graphics: No associated graphics files FROM THE PRESIDENT Agricultural Biotechnology Needs Investment Not Additional Regulation I was recently browsing on the world wide web and came across a list of `Agricultural Biotechnology Products Expected on the Market Within Six Years'. There were over twenty-five different types of product ranging from late ripening fruits (bananas, strawberries, raspberries, tomatoes), vegetables with enhanced properties (such as the potato with higher density starch that when deep fried takes up less fat; and peppers that are sweeter firmer and tastier) and of course a range of disease resistant or herbicide resistant crop plants. There was even a tree that had modified lignin, facilitating its easy removal from cellulose and therefore requiring less energy and bleaching resulting in benefits to both the paper processor and the environment. NEWS $44m in R&D Start large grants announced The Industry Research and Development Board announced on 19th March successful recipients of grants under the first round of the R&D Start program - large grants element. Sixteen projects have been offered a total of $44 million. Biota Announces Zanamivir Will Enter Phase III Clinical Trials in May 1997 Biota Holdings Limited (Australian Stock Exchange: BTA) announced on 24th February that Glaxo Wellcome plc, the Company's development partner, has informed management that Phase III clinical trials of zanamivir, or GG167, for the treatment of influenza, planned to start in 1997, will begin in Australia in May. This Southern Hemisphere trial will be a part of a comprehensive world-wide Phase III programme which will also include two separate pivotal proof of efficacy studies to be initiated in the Northern Hemisphere from October of this year. Dolly - The Science Behind the Sensation Moratorium Reaction Responses in the US Australia Urged to Back Winners Fish Studies Reveal the Good Oil Collaborators Sought for the Roslin and Moredun Stress Proteins and Human Ageing Human Hemoglobin-producing Tobacco The Biotechnology Industry Organization (BIO) and SciQuest(sm) to form Internet Partnership Bioethical Aspects of Biotechnology in the Agrofood Sector - Developing Countries MORE DOLLY NEWS Dolly Cloning Raises Ire of Anti Biotech Lobby Nuclear Transfer in Humans Position Statement on Cloning by the Council for Responsible Genetics New Pharmaceutical Policies LATE NEWS New Company - Enzyme Solutions Pty Ltd COMPANY NEWS Peptech awarded Major Grant for Drug Development New $3.5 Million Microbiology Plant Planned for Brisbane "START" Program Funding for Biotech Australia Rancoo Changes its Name and Appoints a New CEO Profile: Dr Paul Tolstoshev, BresaGen Sheep Cloning an "Important Step" in Transplant Research - Geneticist AGEN Reports Break-even Result New Drug Blows Away Cold and Flu Symptoms BIO SHARES Covering Australian Biotechnology Stocks - compiled by M.J. Playne Introducing a New Corporate Member Gist-brocades in Australia The People and Gist-brocades The Products Cultures Ingredients Preservation Tests Quality Assurance ASIAN NEWS Asian Bioscience Improving Rapidly but Still has a Long Way to Go Foot and mouth disease has finally hit Taiwan after 63 years of absence. REGULATORY NEWS USA EPA Issues New Notification and Screening Requirements for Microbial Biotech Products Canadian Biotech Regulations PATENT NEWS Contributed by Dr. Vivien Santer Extension of Patent Term Re-Instated Discussion Paper on Patentability Standards Official Fees in the European Patent Office being Reduced Philippines to Adopt First to File System Supreme Court Upholds Doctrine of Equivalents in the United States General Patent News ABA NEWS Biotechnology Industry Organization (BIO) AusBiotech Alliance Submissions to Government Reviews Gene Technology Authority Regional Meetings BIO Meeting News from New Zealand by Ian Maddox, President, New Zealand Biotechnology Association Annual General Meeting PRODUCT NEWS Pall and Gelman Sciences Complete Merger Crown Scientific The Eppendorf Model 5171 Micromanipulator The Cell Becomes a Test Tube Eppendorf Release the Titerman for Low Volume Ranges of 0.5 uL to 10 uL Trace Scientific Assayed Cardiac Enzyme Control Mettler Toledo ATCC Express-CheckTM Kit ATCC Introduces VitaCellTM Cell Culture Media & Serum Scientific Associates Stedim Flexboy and Biopharm Sterile Carboys Copyright 1997 Australian Biotechnology Association Ltd.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: Other
Teacher disagreement score0.593
Threshold uncertainty score0.846

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.005
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0020.001
Scholarly communication0.0060.003
Open science0.0010.001
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.4070.340

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.225
Teacher spread0.218 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2010
Admission routes1
Has abstractyes

Explore more

Same venueTSpace (University of Toronto)Same topicTransgenic Plants and ApplicationsFrench-language works237,207